Loading
A phase 2/3 trial of cemiplimab, dexamethasone, docetaxel and ramucirumab in lung cancer, run by SWOG Cancer Research Network, now recruiting.
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) is a phase 2/3, randomised interventional study registered as NCT06616584 by SWOG Cancer Research Network, with a registry enrolment figure of 378 participants, started 2025-05-22 and due to reach its primary completion in 2027-12-31. Interventions recorded: Biospecimen Collection; Cemiplimab; Computed Tomography; Dexamethasone; Docetaxel; Magnetic Resonance Imaging; Ramucirumab. Conditions listed: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "Assignment to S1800E is determined by the LUNGMAP protocol". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Ramucirumab, Dexamethasone, Docetaxel, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Docetaxel, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Ramucirumab, Docetaxel, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Docetaxel, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.